Biomarkers for Malignant and Nonmalignant Diseases of the Pancreas.

This article provides an overview of current and emerging biomarkers for malignant and nonmalignant pancreatic diseases. We highlight the clinical utility and limitations of existing biomarkers and discuss promising developments in molecular, genetic, and fluid-based diagnostics. Improved biomarkers may enhance early detection and risk stratification strategies for benign and malignant pancreatic disease.

• Publication year

  2025

• Venue

  Gastroenterology Clinics of North America

• Publication date

  2025-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.gtc.2025.10.005PMID 41581946
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From Microbiome to Malignancy: Unveiling the Gut Microbiome Dynamics in Pancreatic Carcinogenesis

  2025cited by this paper
• Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review

  2025cited by this paper
• The Clinical Utility of Incorporating Next-Generation Sequencing Results in the Management Algorithm of Pancreatic Cysts.

  2025cited by this paper
• Pancreatic Neuroendocrine Tumors—A Descriptive Study of the Presenting Features in a 20-Year Surgical Resection Cohort at a Tertiary Institution

  2025cited by this paper
• Prospective Validation of a Prediction Model for the Diagnosis of Acute Pancreatitis

  2024cited by this paper
• Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?

  2024cited by this paper
• The role of biomarkers in the early detection of pancreatic cancer

  2024cited by this paper
• Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

  2024cited by this paper
• Pancreatic Cysts.

  2024cited by this paper
• Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer—Advances and Challenges

  2023cited by this paper
• Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma

  2023cited by this paper
• American College of Gastroenterology Guidelines: Management of Acute Pancreatitis.

  2023cited by this paper
• International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas.

  2023cited by this paper
• AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review.

  2023cited by this paper
• Blood-Based Biomarkers in the Diagnosis and Risk Stratification of Pancreatic Cysts.

  2023cited by this paper
• Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma

  2022cited by this paper
• Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring

  2022cited by this paper
• Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts

  2022cited by this paper
• Interleukin-8: An evolving chemokine.

  2022cited by this paper
• Acute Pancreatitis: A Review.

  2021cited by this paper
• Biomarkers of Chronic Pancreatitis: A systematic literature review.

  2021cited by this paper
• Macrophage migration inhibitory factor is an early marker of severe acute pancreatitis based on the revised Atlanta classification

  2021cited by this paper
• The BISAP score, NLR, CRP, or BUN: Which marker best predicts the outcome of acute pancreatitis?

  2021cited by this paper
• A Clinical Overview of Acute and Chronic Pancreatitis: The Medical and Surgical Management

  2021cited by this paper
• Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021.

  2021cited by this paper
• Pancreatic Cancer: A Review.

  2021cited by this paper
• Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?

  2021cited by this paper
• High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9

  2021cited by this paper
• Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls.

  2020cited by this paper
• 68 Ga-DOTATATE PET/CT quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors.

  2020cited by this paper
• 2019 WSES guidelines for the management of severe acute pancreatitis

  2019cited by this paper
• The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors

  2019cited by this paper
• Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.

  2019cited by this paper
• Diagnosis and Management of Chronic Pancreatitis: A Review.

  2019cited by this paper
• Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing.

  2019cited by this paper
• The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.

  2019cited by this paper
• Early Detection of Pancreatic Cancer: Opportunities and Challenges.

  2019cited by this paper
• Diagnostic Performance of Measurement of Fecal Elastase‐1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta‐analysis

  2018cited by this paper
• ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts

  2018cited by this paper
• Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes.

  2018cited by this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification

  2017cited by this paper
• Detection of human elastase isoforms by the ScheBo Pancreatic Elastase 1 Test.

  2017cited by this paper
• Historical review of our knowledge of acute pancreatitis.

  2017cited by this paper
• Lipase or amylase for the diagnosis of acute pancreatitis?

  2017cited by this paper
• Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis.

  2017cited by this paper
• The predictive value of C-reactive protein (CRP) in acute pancreatitis - is interval change in CRP an additional indicator of severity?

  2017cited by this paper
• Development and Diagnostic Accuracy of a Breath Test for Pancreatic Exocrine Insufficiency in Chronic Pancreatitis

  2016cited by this paper
• Clinical practice guideline: management of acute pancreatitis.

  2016cited by this paper
• Hypertriglyceridemic pancreatitis associated with confounding laboratory abnormalities

  2016cited by this paper
• Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis

  2016cited by this paper
• Clinical efficacy of serum lipase subtype analysis for the differential diagnosis of pancreatic and non-pancreatic lipase elevation

  2016cited by this paper
• KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound.

  2015cited by this paper
• A Model to Predict the Severity of Acute Pancreatitis Based on Serum Level of Amylase and Body Mass Index.

  2015cited by this paper
• Pancreatic neuroendocrine tumors: a review.

  2015cited by this paper
• American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts.

  2015cited by this paper
• Proteomic Mucin Profiling for the Identification of Cystic Precursors of Pancreatic Cancer

  2014cited by this paper
• Interleukin-6 in inflammatory and malignant diseases of the pancreas.

  2014cited by this paper
• Precursor lesions of endocrine system neoplasms

  2013cited by this paper
• Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia.

  2013cited by this paper
• miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts

  2012cited by this paper
• Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus

  2012cited by this paper
• Stool DNA testing for the detection of pancreatic cancer

  2012cited by this paper
• Laboratory diagnosis of acute pancreatitis: in search of the Holy Grail

  2012cited by this paper
• DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

  2011cited by this paper
• Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.

  2011cited by this paper
• Comparative studies of mammalian acid lipases: Evidence for a new gene family in mouse and rat (Lipo).

  2010cited by this paper
• Diagnostic Accuracy of Interleukin-6 and Interleukin-8 in Predicting Severe Acute Pancreatitis: A Meta-Analysis

  2010cited by this paper
• The early prediction of mortality in acute pancreatitis: a large population-based study

  2008cited by this paper
• ROLE OF TUMOR NECROSIS FACTOR-&agr; IN ACUTE PANCREATITIS: FROM BIOLOGICAL BASIS TO CLINICAL EVIDENCE

  2007cited by this paper
• Biochemical markers of acute pancreatitis

  2006cited by this paper
• Clinical value of rapid urine trypsinogen-2 test strip, urinary trypsinogen activation peptide, and serum and urinary activation peptide of carboxypeptidase B in acute pancreatitis.

  2005cited by this paper
• Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis.

  2005cited by this paper
• Serum Trypsinogen Activation Peptide in the Assessment of the Diagnosis and Severity of Acute Pancreatic Damage: A Pilot Study Using a New Determination Technique

  2004cited by this paper
• C-reactive protein: a critical update.

  2003cited by this paper
• SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions

  2003cited by this paper
• Laboratory diagnostic tests in acute pancreatitis.

  2002cited by this paper
• A comparison of serum trypsinogen-2 and trypsin-2-α1-antitrypsin complex with lipase and amylase in the diagnosis and assessment of severity in the early phase of acute pancreatitis

  2001cited by this paper
• Faecal Elastase-1: Lyophilization of Stool Samples Prevents False Low Results in Diarrhoea

  2001cited by this paper
• Function of C-reactive protein

  2000cited by this paper
• Routine α-Amylase Assay Using Protected 4-Nitrophenyl-1,4-α-d-maltoheptaoside and a Novel α-Glucosidase

  2000cited by this paper
• Rapid measurement of urinary trypsinogen-2 as a screening test for acute pancreatitis.

  1997cited by this paper
• lnterleukin‐8 and neutrophil activation in acute pancreatitis

  1992cited by this paper
• Lipase isoforms and amylase isoenzymes: assays and application in the diagnosis of acute pancreatitis.

  1991cited by this paper
• Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis.

  1991cited by this paper
• Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis.

  1990cited by this paper
• Where does serum amylase come from and where does it go?

  1990cited by this paper
• Trypsin-like immunoreactivity as a test for pancreatic insufficiency.

  1984cited by this paper
• Amylase.

  1952cited by this paper

• No citing papers are available for this paper.